Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery

Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery - a Pilot Study

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01524315

Enrollment

Registered

2012-02-01

Start date

2012-02-01

Completion date

2015-02-02

Last updated

2021-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acidosis, Lactic, Heart Failure, Thiamine Deficiency

Keywords

Thiamine, Vitamin B1, Thiamine Deficiency, Thiamine supplementation, Cardiac surgery, Lactic Acid

Brief summary

The objective of this study is to determine whether preoperative parenteral thiamin supplementation does prevent the intra and early postoperative increase of lactate and whether this effect is related to the extent of thiamine deficiency in patients undergoing heart surgery. In addition the prevalence of major thiamin deficiency in patient undergoing heart surgery will be determined.

Detailed description

Thiamine (vitamin B1) is a water-soluble vitamin and is involved in several stages of intermediate metabolism which are important for producing energy. Severe thiamin deficiency has been associated with severe lactic acidosis and clinical symptoms of life threatening heart failure. To date, no study has evaluated thiamine levels in patients undergoing heart surgery and the prevalence of thiamine deficiency is not known. Furthermore it is unknown whether moderately reduced thiamin levels are associated with mild forms of perioperative cardiac failure necessitating prolonged inotropic support. In this prospective double blind randomised controlled trial of the effect of a parenteral infusion of thiamin before induction of anaesthesia we will investigate the effect on perioperative lactate increase as primary outcome and extent and duration of inotropic support after cardiac surgery. In addition the pharmacokinetics of a intravenous infusion of 300 mg of thiamin on erythrocyte thiamin content and the amount of thiamine excreted in the 24 hours via the urine will be determined. Baseline thiamin levels in erythrocytes before surgery, as well as nutrition history and body composition will be evaluated as effect modifier.

Interventions

DRUGVitamin B1-ratiopharm

300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative

DRUGPlacebo

100 ml normal saline, intravenous, preoperative

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age 18 - 100 years * planned heart surgery * signed informed consent

Exclusion criteria

* pregnancy and lactation * known allergic reaction to the drugs used * mental condition rendering the patient unable to give informed consent * inability or contraindications to perform study procedures

Design outcomes

Primary

Measure	Time frame	Description
Thiamine status and lactate levels	perioperative	Thiamine status: functional parameter - erythrocyte transketolase (α-ETK) expressed as TPP (thiamine pyrophosphate); quantity of vitamin B1 in urine and blood concentrations Lactate levels: lactate levels will be determined by blood gas analysis (BGA) within the routine check.

Secondary

Measure	Time frame	Description
Prevalence of thiamine deficiency, identification of body composition and length of hospital and ICU stay	2-3 weeks	Thiamine status: functional parameter - erythrocyte transketolase (α-ETK) expressed as TPP (thiamine pyrophosphate); Body composition: measuring with bioelectrical impedance analysis (BIA) Length of ICU and hospital stay;

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026